Molecular Imaging and Therapeutics

UCSF's Henry VanBrocklin Receives the Prestigious Aebersold Award at SNMMI

Congratulations to Henry VanBrocklin, PhD, FSNMMI, FSRS, recipient of the 2023 Paul C. Aebersold Award! Dr. VanBrocklin is a professor in the Department of Radiology and Biomedical Imaging and director of the Radiopharmaceutical Research Program in the Center for Molecular and Functional Imaging at the University of California, San Francisco (UCSF). He is also one of the core faculty for the Master's in Biomedical Imaging (MSBI) program. Dr. VanBrocklin received the award on June 25 at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Chicago.

UCSF Radiology MI&T Experts Review Dosimetry in Radionuclide Therapy

A team of faculty and fellows from the Molecular Imaging and Therapeutics (MI&T) section at the UC San Francisco Department of Radiology and Biomedical Imaging recently wrote a review on dosimetry in radionuclide therapy for a high-impact journal.

The Exploration of PSMA PET as a Possible Theranostic Agent in Thyroid Cancer

Courtney Lawhn Heath, MD, took the lead on a recent prospective pilot study, published in EJNMMI Research, to determine the feasibility and utility of [68Ga]Ga-PSMA-11 PET/MRI in thyroid cancer patients.

The Future of Molecular Imaging and Prostate Cancer

Because treatment for prostate cancer is highly individualized, molecular imaging technologies are helping to improve the ways in which prostate cancer is diagnosed and treated.

UCSF Radiology Introduces A New Molecular Imaging and Therapeutics (MI&T) Clinical Section

To meet the challenges introduced at the cutting edge of a rapidly growing clinical field, the UCSF Radiology is inaugurating a new clinical section, Molecular Imaging and Therapeutics (MI&T).